N Engl J Med. 2022;387(8):715–726. doi: 10.1056/NEJMoa2201302
Phase 3 trial of olokizumab, a direct inhibitor of the IL-6 ligand, demonstrates superiority to placebo with respect to an ACR20 response at week 12 and noninferiority to adalimumab (all combined with methotrexate), in patients with RA.
Although there are drugs that target the IL-6 receptor currently used to treat RA, to date, there are no approved inhibitors of the IL-6 ligand. To this end, Smolen, et al. evaluated the efficacy and safety of subcutaneous olokizumab (humanised monoclonal anti-IL-6 antibody) in the treatment of RA, with promising results.